Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2025Frontiers in ImmunologyOpen Access

Single-cell profiling uncovers PTPRG-driven stemness in malignant plasma cells and signatures of treatment failure in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJiewen TanJZJinman ZhongYHYueping He

Discussion

Loading...

Member takes

Overview

Single-cell profiling reveals PTPRG-driven stemness in malignant plasma cells, indicating new biomarkers and therapeutic targets.

Key Points

  • Malignant plasma cells exhibit significant heterogeneity, highlighting PTPRG's role in treatment resistance.
  • Analysis of over 103,000 single-cell transcriptomes identified five plasma cell subclusters linked to patient survival outcomes.
  • Investigations unveiled that a specific MalPlasma3 subcluster is enriched in treatment-resistant cells and active pathways associated with poor prognosis.
  • This research suggests that targeting PTPRG and associated pathways may improve outcomes for multiple myeloma patients.

Cite This Study

Tan et al. (2025) studied this question.

synapsesocial.com/papers/68d435cf713b0b5dfea74e53https://doi.org/10.3389/fimmu.2025.1658028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease2025
  2. 2Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies2025 · 1 citations
  3. 3Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma2025 · 1 citations
  4. 4Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  5. 5Dissecting the multiple myeloma survival niche to improve novel treatment strategies2025